Answers are grounded in this paper and cite their sources.
Chronic pathologies that disable over time, such as hypertension and type 2 diabetes, remain among the top targets of international studies and approaches. That’s why the scientists, as well as the staff of the practical bases, have nothing left but to impose the development and implementation of the new preparations, which would be able to meet their needs. An important step would be to synthesize drug molecules with positive effects in concomitant pathologies, which most often meet in pairs or complement each other through the adverse effects they produce on the human body. Such a preparation, which is currently approached through the prism of the multitude of positive effects, is in full company of implementation in the treatment of several chronic pathologies such as type 2 diabetes mellitus, chronic heart failure, chronic renal failure and makes part of the group of SGLT 2 inhibitors is the dapagliflozin.The antihypertensive effect of dapagliflozin is relevant and requires a well-documented analysis in this direction
No takes yet. Share an insight, caveat, or question.
Cotelea et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: